Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ECOR
electroCore, Inc. Common Stock
stock NASDAQ

At Close
Aug 7, 2026 3:59:54 PM EDT
8.22USD+25.114%(+1.65)213,988
6.91Bid   9.56Ask   2.65Spread
Pre-market
0.00USD-100.000%(-6.53)0
After-hours
Aug 7, 2026 4:52:30 PM EDT
7.90USD-3.893%(-0.32)2,846
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 25, 2022
01:17PM EST  ElectroCore Granted U.S. Patent Titled 'Mobile phone for treating a patient with seizures'   Benzinga
08:00AM EST  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the possible mechanistic or clinical role of nVNS for the acute treatment of stroke will be presented at the American Heart Associations 2022 International Stroke Conference, February 9th 11th, 2022, in New Orleans, Louisiana.   GlobeNewswire Inc
Jan 19, 2022
06:32AM EST  HC Wainwright & Co. Maintains Buy on electroCore, Lowers Price Target to $2.75   Benzinga
Jan 18, 2022
05:10PM EST  ElectroCore Files For Mixed Shelf Of Up To $75M   Benzinga
08:23AM EST  electroCore Anticipates FY21 Revenue $5.5M, Up 55% YoY   Benzinga
08:00AM EST  electroCore, Inc. (Nasdaq: ECOR) today published a letter from the companys Board of Directors to shareholders. The letter is included in its entirety, below:   GlobeNewswire Inc
Jan 12, 2022
08:08AM EST  electroCore's gammaCore Non-Invasive Vagus Nerve Stimulation Receives Breakthrough Device Designation For Treatment Of Posttraumatic Stress Disorder   Benzinga
08:00AM EST  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCorenVNS device has received Breakthrough Designation from the U.S.Food and Drug Administration (FDA) for the treatment of posttraumatic stress disorder (PTSD) after showing a reduction of symptoms of PTSD by 31% when compared to sham.   GlobeNewswire Inc
Jan 11, 2022
08:07AM EST  electroCore Announces Launch Of e-Commerce Shop   Benzinga
08:00AM EST  electroCore, Inc. Broadens Patient Access to gammaCore with Launch   GlobeNewswire Inc
06:38AM EST  ElectroCore's Non-invasive Nerve Stimulator Effective Against Migraine   Benzinga
Jan 10, 2022
04:02PM EST  electroCore Highlights Publication Of PREMIUM II Trial Of gammaCore For Prevention Of Migraine   Benzinga
04:01PM EST  electroCore Announces Publication of PREMIUM II Trial of gammaCore   GlobeNewswire Inc
Jan 4, 2022
08:00AM EST  electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The conference is taking place virtually from January 10 - 13, 2022. Details for access to the presentation are as follows:   GlobeNewswire Inc
Dec 16, 2021
08:12AM EST  electroCore Says Entered Into Agreements With Melidonia Health, Cyrus Medical Technologies, Express Medical Solutions   Benzinga
08:00AM EST  electroCore, Inc. Provides Update on Global Distribution Partners   GlobeNewswire Inc
Dec 15, 2021
08:03AM EST  electroCore Highlights Launch Of New Online Shop In UK   Benzinga
08:00AM EST  electroCore, Inc. Announces The Launch of a New Online Shop in the   GlobeNewswire Inc
Dec 14, 2021
08:19AM EST  electroCore Offers Update On Non-Invasive Vagal Nerve Stimulation Candidate To Treat Post Traumatic Stress Disorder   Benzinga
08:00AM EST  electroCore, Inc.(the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on the ongoing clinical research to assess the potential of gammaCore (non-invasive vagal nerve stimulation; nVNS) to treat Post Traumatic Stress Disorder (PTSD).   GlobeNewswire Inc
Dec 13, 2021
08:56AM EST  electroCore Announces US Patent For Stroke And TIA Treatment   Benzinga
08:55AM EST  electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,191,953 to the Company, relating to the treatment of stroke symptoms.   GlobeNewswire Inc
Dec 7, 2021
09:36AM EST  elecroCore Shares Quiet Following US Patent & Trademark Office Abstract For Co.'s 'Systems and methods for vagal nerve stimulation'   Benzinga
Nov 11, 2021
08:00AM EST  electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be available for virtual one-on-one meetings at the Canaccord Genuity MedTech & Diagnostics Forum. The conference is taking place virtually November 18, 2021. Details are as follows:   GlobeNewswire Inc
Nov 5, 2021
09:22AM EDT  electroCore Q3 EPS $(0.06) Beats $(0.08) Estimate, Sales $1.49M Miss $1.56M Estimate   Benzinga
Nov 4, 2021
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Oct 21, 2021
08:00AM EDT  electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November 4, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.   GlobeNewswire Inc
Oct 20, 2021
08:00AM EDT  electroCore Announces Publication Reviewing the Prescribing of   GlobeNewswire Inc
Oct 14, 2021
08:00AM EDT  electroCore Announces Regulatory Approval in Canada to Treat   GlobeNewswire Inc
Oct 12, 2021
08:18AM EDT  ElectroCore Sees Q3 2021 Revenue ~$1.5M Vs $1.56M Est   Benzinga
08:00AM EDT  -- Third quarter 2021 revenue expected to be approximately $1.5 million -- Net cash used to fund operations in the third quarter 2021 of approximately $3.5 million   GlobeNewswire Inc
Oct 7, 2021
08:17AM EDT  ElectroCore Announces Acceptance Of Motion To Dismiss In Federal Court Securities Class Action Suit   Benzinga
08:00AM EDT  electroCore Announces Acceptance of Motion to Dismiss in the   GlobeNewswire Inc
Sep 30, 2021
09:19AM EDT  electroCore To Present At Cantor Fitzgerald Virtual Global Healthcare Conference Today   Benzinga
09:06AM EDT  electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference has been rescheduled to today, September 30, 2021 at 12:40 PM eastern time.   GlobeNewswire Inc
Sep 29, 2021
08:18AM EDT  electroCore Announces Open Access And Submission Of Manuscript From SAVIOR-1 Study Of Non-Invasive Vagus Nerve Stimulation (nVNS) In Hospitalized COVID-19 Patients   Benzinga
08:00AM EDT  electroCore Announces Open Access and Submission of Manuscript   GlobeNewswire Inc
Sep 23, 2021
08:00AM EDT  electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference.   GlobeNewswire Inc
Sep 21, 2021
01:55PM EDT  ElectroCore Granted U.S. Patent Titled 'Devices and methods for nerve stimulation'   Benzinga
Sep 20, 2021
08:23AM EDT  electroCore Announces Peter Cuneo As Board Chairman   Benzinga
Sep 15, 2021
08:03AM EDT  ElectroCore Announces New Patent Expanding Claims Related to Delivery Of Non-Invasive Vagus Nerve Stimulation Therapy Using Mobile Devices   Benzinga
08:00AM EDT  electroCore Announces New Patent Expanding Claims Related to   GlobeNewswire Inc
Sep 14, 2021
08:20AM EDT  electroCore Announces 510 Clearance Of gammaCore Non-Invasive Vagus Nerve Stimulation To Treat Paroxysmal Hemicrania And Hemicrania Continua   Benzinga
08:00AM EDT  electroCore Announces 510(k) Clearance of   GlobeNewswire Inc
Sep 13, 2021
09:40AM EDT  ElectroCore Granted FDA Approval For Gammacore Sapphire Neurology Treatment   Benzinga
Aug 31, 2021
08:00AM EDT  electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation at the HC Wainwright 23rd Annual Global Investment Conference. The conference is taking place virtually from September 13 - 15, 2021. Details for the presentation are as follows:   GlobeNewswire Inc
Aug 24, 2021
10:46AM EDT  ElectroCore Granted U.S. Patent Titled 'Mobile phone using non-invasive nerve stimulation   Benzinga
08:22AM EDT  electroCore Announces New Reseller Agreement With Red One Medical Devices, LLC.   Benzinga
08:00AM EDT  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LLC. (Red One). The partnership will further expand availability of electroCores gammaCore platform in the federal marketplace.   GlobeNewswire Inc
Aug 14, 2021
06:31AM EDT  ECOR: Impressive Growth: Invigorating Guidance   Benzinga
Aug 10, 2021
08:00AM EDT  Study of Non-Invasive Vagus Nerve Stimulation (nVNS) Shows   GlobeNewswire Inc
Aug 5, 2021
04:48PM EDT  ElectroCore Sees Q3 Sales Of At Least $1.5M Vs. $1.59M Est.   Benzinga
04:47PM EDT  electroCore Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $1.27M Miss $1.32M Estimate   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 4, 2021
08:51AM EDT  ElectroCore Highlights Publication In PharmacoEconomics   Benzinga
08:00AM EDT  electroCore Announces Publication in PharmacoEconomics Reiterating   GlobeNewswire Inc
Aug 2, 2021
08:00AM EDT  electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation and be available for virtual one-on-one meetings at the Canaccord Genuity Growth Conference. The conference is taking place virtually from August 10 - 12, 2021. Details for the presentation are as follows:   GlobeNewswire Inc
Jul 27, 2021
06:03PM EDT  ElectroCore Analyst: Nerve Stimulation Market Opportunity Is Large   Benzinga
11:13AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2021   Benzinga
11:13AM EDT  ElectroCore Stock Is Trading Higher As Ladenburg Initiates Coverage With $3 Price Target, Buy Rating   Benzinga
11:13AM EDT  electroCore Announces Issuance Of US Patent For Migraine Treatment Using Smartphones   Benzinga
11:13AM EDT  Ladenburg Thalmann Initiates Coverage On electroCore with Buy Rating, Announces Price Target of $3   Benzinga
Jul 22, 2021
08:00AM EDT  electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the second quarter ended June 30, 2021 after the close of the market on Thursday, August 5, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.   GlobeNewswire Inc
Jul 19, 2021
08:00AM EDT  electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, is to receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021.   GlobeNewswire Inc
Jul 13, 2021
08:09AM EDT  electroCore Sees Q2 Sales ~$1.3M vs $1.32M Estimate, Net Cash Used To Fund Operations ~$3.2M   Benzinga
08:00AM EDT  -- Second-Quarter 2021 revenue expected to be approximately$1.3 million -- Net cash used to fund operations inthe second quarter 2021 of approximately $3.2 million -- Follow on offering subsequent to June 30, 2021 added $18.8 million to cash balance   GlobeNewswire Inc
Jul 9, 2021
08:03AM EDT  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, CEO will present a company overview and be available for 1x1 meetings at the following upcoming conference:   GlobeNewswire Inc
Jul 7, 2021
05:04PM EDT  electroCore Form 4 Filing's Show 3 Executives Purchased A Total Of 200K Shares At $1.00   Benzinga
Jun 30, 2021
12:23PM EDT  Mid-Day Market Update: Barnes & Noble Education Drops Following Q4 Results; Aerovate Therapeutics Shares Surge   Benzinga
11:46AM EDT  ElectroCore Stock Dives On $18M Equity Raise Issued At Deep Discount Of 32%   Benzinga
08:32AM EDT  electroCore Prices 18M Share Common Stock Offering At $1/Share   Benzinga
08:30AM EDT  electroCore Announces Pricing of $18.0 Million Public Offering of   GlobeNewswire Inc
Jun 29, 2021
04:02PM EDT  electroCore Reports Common Stock Offering, No Size Disclosed   Benzinga
04:01PM EDT  electroCore Announces Proposed Public Offering of Common Stock   GlobeNewswire Inc
Jun 24, 2021
08:21AM EDT  electroCore Highlights Publication Of Study On Effect Of Non-Invasive Vagus Nerve Stimulation In Cognitive Performance Caused By Sleep Deprivation   Benzinga
08:00AM EDT  electroCore Announces Publication of Study on the Effect of   GlobeNewswire Inc
Jun 23, 2021
08:00AM EDT  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement withKromax International Corporation to serve as the exclusive distributor of the gammaCore Sapphire non-invasive vagus nerve stimulator (nVNS) in Taiwan and China.   GlobeNewswire Inc
Jun 16, 2021
08:08AM EDT  electroCore Reports Will Join Russell Microcap Index, Effective Jun. 28   Benzinga
08:00AM EDT  electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today the addition of its stock to the broad-market Russell Microcap Index after its 2021 annual reconstitution, effective after the open of trading on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.   GlobeNewswire Inc
Jun 9, 2021
08:00AM EDT  electroCore Completes Sale of $1.4 Million of NJ NOL Tax   GlobeNewswire Inc
Jun 2, 2021
07:33AM EDT  electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson's Disease Patients   Benzinga
07:30AM EDT  electroCore Announces Publication of Study on Non-Invasive Vagus   GlobeNewswire Inc
May 26, 2021
07:30AM EDT  electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several investor conferences during the month of June. The conferencing details are as follows:   GlobeNewswire Inc
May 6, 2021
05:28PM EDT  electroCore Q1 EPS $(0.11) Up From $(0.27) YoY, Sales $1.20M Beat $1.08M Estimate   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
May 5, 2021
10:06AM EDT  Preview: electroCore's Earnings   Benzinga
May 4, 2021
08:16AM EDT  ElectroCore Announces U.S. Department Of Veterans Affairs Study Of GammaCore Sapphire For Treatment Of Post-Traumatic Headaches   Benzinga
08:00AM EDT  electroCore, Inc. Announces U.S. Department of Veterans Affairs   GlobeNewswire Inc
Apr 29, 2021
08:00AM EDT  electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2021 after the close of the market on Thursday, May 6, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.   GlobeNewswire Inc
Apr 26, 2021
08:05AM EDT  electroCore Highlights Johns Hopkins School Of Medicine Study Of Non-Invasive Vagus Nerve Stimulation for Symptomatic Exacerbation of Nausea in Patients with Gastroparesis and Related Disorders   Benzinga
08:00AM EDT  electroCore, Inc. Announces Johns Hopkins University School of   GlobeNewswire Inc
Apr 20, 2021
08:10AM EDT  ElectroCore Announces Exclusive Agreement With East Agency For Qatar   Benzinga
08:00AM EDT  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement withEast Agency to serve as the exclusive distributor of the gammaCore Sapphire non-invasive vagus nerve stimulator (nVNS) to patients suffering from primary headache disorders in Qatar.   GlobeNewswire Inc
Apr 15, 2021
08:01AM EDT  electroCore Announces Publication in Nature Reviews: Neurology Highlighting the Role of Non-Invasive Vagus Nerve Stimulation (nVNS) as an Emerging Treatment for Cluster Headache   Benzinga
07:59AM EDT  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, Cluster headache pathophysiology insights from current and emerging treatments,by Drs. Diana Wei and Peter Goadsby in Nature Reviews: Neurology.1   GlobeNewswire Inc
Apr 13, 2021
08:00AM EDT  electroCore Expects Q1 Sales To be More Than $1.1M   Benzinga
07:59AM EDT  -- First-quarter 2021 revenue expected to be more than $1.1 million -- Net cash used for the first quarter 2021 of approximately $4.1 million   GlobeNewswire Inc
Apr 8, 2021
09:07AM EDT  ElectroCore's Stock Is Trading Higher As nVNS Decreases Certain COVID-19-Associated Biomarkers   Benzinga
08:19AM EDT  ElectroCore Announces Top-line Results From The SAVIOR-1 Study   RTTNews
07:59AM EDT  electroCore Reports Top-Line Results From SAVIOR-1 Study Of Non-Invasive Vagus Nerve Stimulation In Hospitalized COVID-19 Patients: 'nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of treatment'   Benzinga
07:59AM EDT  electroCore Announces Top Line Results from SAVIOR-1 study of   GlobeNewswire Inc
Apr 5, 2021
09:34AM EDT  ElectroCore's Stock Is Trading Higher After Its Nerve Stimulator Wins Canadian Approval For Migraine   Benzinga
08:00AM EDT  electroCore Announces Health Canada Approval For Promotion And Sale Of gammaCore Sapphire Family Of Products   Benzinga
07:59AM EDT  electroCore, Inc. Announces Regulatory Approval in Canada   GlobeNewswire Inc
Mar 23, 2021
08:05AM EDT  electroCore, Inc. Announces Exclusive Distribution Agreement With Silvert Medical Nv-Sa. For Western Europe; Initial Term Is Three Years, Financial Details Not Disclosed   Benzinga
08:00AM EDT  electroCore, Inc. Announces Exclusive Distribution Agreement with   GlobeNewswire Inc
Mar 15, 2021
08:56AM EDT  Chief Medical Officer of electroCore, Inc. Peter Staats, M.D. Describes Potential At-Home Solutions to Reduce Common COVID-19 Symptoms   Business Wire
Mar 11, 2021
04:34PM EST  electroCore Q4 EPS $(0.14) Misses $(0.10) Estimate, Sales $928.00K Beat $890.00K Estimate   Benzinga
04:05PM EST  Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019   GlobeNewswire Inc
03:35AM EST  Earnings Scheduled For March 11, 2021   Benzinga
Mar 4, 2021
08:30AM EST  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the fourth quarter and year ended December 31, 2020 after the close of the market on Thursday, March 11, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.   GlobeNewswire Inc
Mar 3, 2021
04:30PM EST  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in two upcoming investor conferences.   GlobeNewswire Inc
Mar 1, 2021
02:37PM EST  Mid-Afternoon Market Update: Crud Oil Down Over 1%; Morphic Shares Spike Higher   Benzinga
12:17PM EST  Mid-Day Market Update: Dow Jumps Over 600 Points; CorMedix Shares Plummet   Benzinga
10:55AM EST  Shares of electroCore, Inc. (ECOR) are rising more than 50% Monday morning after the company entered into an exclusive distribution agreement with medical device distributor, Medistar for the company's non-invasive vagus nerve stimulator, gammaCore Sapphire.   RTTNews
10:13AM EST  Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Receives FDA Approval For COVID-19 Vaccine   Benzinga
06:10AM EST  ElectroCore's Shares Are Trading Higher After Australia Ok'd Vagus Nerve Stimulator For Headaches   Benzinga
05:23AM EST  electroCore Shares Trading Up 75% Premarket After Co Announced on Sunday an Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia   Benzinga
Feb 28, 2021
09:50PM EST  electroCore Inc. (ECOR) said that it has reached an agreement with Medistar2 PTY whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire non-invasive vagus nerve stimulator or nVNS in Australia, supplying therapy to patients suffering with primary headache disorders.   RTTNews
04:00PM EST  electroCore Inc. Announces Exclusive Distribution Agreement with   GlobeNewswire Inc
Feb 24, 2021
09:39AM EST  ElectroCore Concludes Enrollment In COVID-19 Study Evaluating Vagus Nerve Stimulation   Benzinga
07:48AM EST  electroCore Announces Completion Of Patient Enrollment In SAVIOR-1 Trial To 'Evaluate the Effect of Non-Invasive Electrical Vagus Nerve Stimulation on Respiratory Symptoms due to COVID-19'   Benzinga
Feb 23, 2021
08:19AM EST  electroCore Announces Two-Year Extension Of gammaCore Listing In NHS Supply Chain Catalogue   Benzinga
08:00AM EST  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore will continue to be listed in the NHS Supply Chain catalogue for an additional two years through June 3, 2023. The original listing, which commenced on June 4, 2019, was scheduled to terminate on June 3, 2021.   GlobeNewswire Inc
Feb 16, 2021
08:32AM EST  electroCore Announces 510(k) Clearance From The FDA For Its gammaCore Non-Invasive Vagus Nerve Stimulation To Treat Adolescent Migraine   Benzinga
08:00AM EST  electroCore Announces 510(k) Clearance of   GlobeNewswire Inc
Feb 11, 2021
08:00AM EST  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the completion of patient enrollment in SAVIOR-1, a prospective, randomized, controlled study evaluating vagus nerve stimulation in patients who exhibit respiratory symptoms due to COVID-19. This study is being conducted at the Hospital Clnico Universitario de Valencia, Spain.   GlobeNewswire Inc
Feb 9, 2021
08:08AM EST  ElectroCore Announces Publication Of Study On Non-Invasive Vagus Nerve Stimulation To Reduce Ileus After Major Colorectal Surgery   Benzinga
Feb 3, 2021
08:00AM EST  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which is being held virtually February 17-19, 2021.   GlobeNewswire Inc
Feb 2, 2021
08:02AM EST  ElectroCore Announces Full Enrollment Of TR-VENUS Study Of Non-Invasive Vagal Nerve Stimulation For Acute Treatment Of Stroke   Benzinga
08:00AM EST  electroCore Announces Full Enrollment of TR-VENUS study of   GlobeNewswire Inc
Jan 27, 2021
01:26PM EST  ElectroCore Issued European Patent Titled 'DEVICE FOR NON-INVASIVE VAGAL NERVE STIMULATION TO TREAT DISORDERS'   Benzinga
08:10AM EST  ElectroCore Announces Inclusion Of GammaCore Sapphire In New NHS England And NHS Improvement MedTech Funding Mandate Policy 2021/22   Benzinga
08:00AM EST  electroCore, Inc. Announces Inclusion of gammaCore   GlobeNewswire Inc
Jan 26, 2021
08:08AM EST  ElectroCore Announces Exclusive Distribution Agreement With RSK Medical In Canada   Benzinga
08:00AM EST  electroCore, Inc. Announces Exclusive Distribution Agreement with   GlobeNewswire Inc
Jan 21, 2021
10:02AM EST  Looking Into electroCore's Return On Capital Employed   Benzinga
08:07AM EST  electroCore Reports Scottish Health Technology Group Recommendation For Use Of gammaCore In Cluster Headache Patients, No Terms Disclosed   Benzinga
08:00AM EST  electroCore, Inc. Announces Scottish Health Technology Group   GlobeNewswire Inc
Jan 19, 2021
08:04AM EST  ElectroCore Announces Establishment Of Unique Level II HCPCS Code For 'Non-Invasive Vagus Nerve Stimulator'   Benzinga
08:00AM EST  electroCore, Inc. Announces the Establishment of a Unique Level II   GlobeNewswire Inc
Jan 11, 2021
08:06AM EST  electroCore Expects FY20 Sales At The Upper Range of $3.3M-$3.5M Vs. $3.41M Est.   Benzinga
08:00AM EST  Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M   GlobeNewswire Inc
Dec 31, 2020
10:25AM EST  Hearing ElectroCore Issued US Patent No. 10,874,857 By The US Patent And Trademark Office, Titled: Mobile Phone Using Non-Invasive Nerve Stimulation   Benzinga
Dec 21, 2020
04:08PM EST  electroCore, Inc. Announces Agreement With Pro Medical Baltic To Be Exclusive Distributor For gammaCore Sapphire In Eastern Europe   Benzinga
04:05PM EST  electroCore, Inc. Announces Agreement with Pro Medical Baltic to   GlobeNewswire Inc
Dec 8, 2020
08:02AM EST  UPDATE: electroCore Sees Complete Results Of PREMIUM II Study Published In Early 2021 In Peer Reviewed Neurology Journal   Benzinga
08:01AM EST  electroCore Reports Top-Line Results From PREMIUM II Migraine Prevention Study   Benzinga
08:00AM EST  electroCore Announces Positive Top-Line Results from PREMIUM II   GlobeNewswire Inc
Dec 7, 2020
04:30PM EST  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the 13th Annual LD Micro Main Event Conference.   GlobeNewswire Inc
Dec 1, 2020
08:08AM EST  electroCore Announces Its gammaCore Nerve Stimulator National Institute On Drug Abuse-Sponsored Study Has   Benzinga
08:00AM EST  electroCore Announces Selection of gammaCore for National   GlobeNewswire Inc
Nov 12, 2020
04:54PM EST  Recap: electroCore Q3 Earnings   Benzinga
04:04PM EST  electroCore Q3 EPS $(0.10) Beats $(0.14) Estimate, Sales $1.10M Beat $940.00K Estimate   Benzinga
04:01PM EST  Revenue growth of 44% over the second quarter of 2020 and 58% over the third quarter of 2019   GlobeNewswire Inc
08:00AM EST  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive Officer, and Brian Posner, Chief Financial Officer, will participate in two upcoming investor conferences:   GlobeNewswire Inc
04:18AM EST  Earnings Scheduled For November 12, 2020   Benzinga
Nov 11, 2020
10:10AM EST  A Preview Of electroCore's Earnings   Benzinga
Oct 23, 2020
10:48AM EDT  Benzinga's Top Upgrades, Downgrades For October 23, 2020   Benzinga
06:11AM EDT  Brookline Capital Initiates Coverage On electroCore with Buy Rating, Announces Price Target of $5   Benzinga
Oct 21, 2020
08:17AM EDT  ElectroCore Appoints Sylvester Steele VP And General Manager Of Government Channels Business Unit   RTTNews
08:00AM EDT  electroCore, Inc. Appoints Business Development Leader and US Navy   GlobeNewswire Inc
Oct 13, 2020
08:16AM EDT  electroCore Sees Q3 Sales Exceeding $1M   Benzinga
08:00AM EDT  Third quarter 2020 Revenue expected to exceed $1 million, representing an increase of greater than 35% sequentially and greater than 50% over Q3 2019   GlobeNewswire Inc
Oct 1, 2020
08:45AM EDT  ITP program providing reimbursement for gammaCore extended to March. 31, 2021 with option for additional three years   GlobeNewswire Inc
Sep 30, 2020
09:35AM EDT  Benzinga's Top Upgrades, Downgrades For September 30, 2020   Benzinga
08:24AM EDT  Maxim Group Initiates Coverage On electroCore with Buy Rating, Announces Price Target of $3   Benzinga
08:00AM EDT  electroCore Announces Department of Veterans Affairs Sponsored   GlobeNewswire Inc
Sep 24, 2020
11:13AM EDT  ElectroCore shares are trading higher after the company announced an agreement with UpScript to be the exclusive online telehealth provider for gammaCore Sapphire.   Benzinga
11:01AM EDT  Why ElectroCore's Stock Trader Higher Today   Benzinga
08:16AM EDT  electroCore Announces Agreement with UpScript, LLC to be Exclusive Online Telehealth Provider for gammaCore Sapphire CV   Benzinga
08:00AM EDT  electroCore Announces Agreement with UpScript, LLC to be Exclusive   GlobeNewswire Inc
Sep 23, 2020
04:05PM EDT  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive officer, will participate in a fireside chat at the JMP Securities MedTech Bio Summit, which is being held virtually October 1-2, 2020.   GlobeNewswire Inc
Sep 11, 2020
08:00AM EDT  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at the HC Wainwright Virtual 22nd Annual Global Investment Conference, which is being held from September 14-16, 2020.   GlobeNewswire Inc
Aug 27, 2020
08:03AM EDT  ElectroCore Announces Publication In Brain Stimulation Highlighting Non-Invasive Vagal Nerve Stimulation's Potential Role In Treatment Of PTSD   Benzinga
08:01AM EDT  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, Non-invasive vagal nerve stimulation decreases brain activity during trauma scripts1,by Wittbrodt, Bremner et. al. in the journalBrain Stimulation.   GlobeNewswire Inc
Aug 24, 2020
12:36PM EDT  ElectroCore Wins Veterans Affair Contract For '6515--gammaCore Sapphire 3 Non-Invasive Vagus Nerve Stimulator'   Benzinga
07:35AM EDT  ElectroCore Wins a 6-Month Contract From the NHS England for Treatment of Cluster Headaches   Benzinga
07:30AM EDT  electroCore, Inc. Announces Publication of a Voluntary ex-ante   GlobeNewswire Inc
Aug 14, 2020
07:18AM EDT  BTIG Upgrades electroCore to Buy, Announces $3.5 Price Target   Benzinga
06:38AM EDT  HC Wainwright & Co. Maintains Buy on electroCore, Raises Price Target to $3   Benzinga
Aug 13, 2020
04:54PM EDT  Recap: electroCore Q2 Earnings   Benzinga
04:25PM EDT  electroCore Q2 EPS $(0.13) Beats $(0.21) Estimate, Sales $753.00K Miss $860.00K Estimate   Benzinga
04:06PM EDT  Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations   GlobeNewswire Inc
04:03AM EDT  Earnings Scheduled For August 13, 2020   Benzinga
Jul 31, 2020
04:45PM EDT  04:45 Friday, July 31, 2020   RTTNews
10:15AM EDT  Shares of electroCore, Inc. (ECOR) are gaining almost 56 percent or $0.86 in Friday's morning trade at $2.40.   RTTNews
Jul 30, 2020
05:25PM EDT  ElectroCore Says gammaCore Sapphire CV Will Be Available For Distribution For $1,750; ElectroCore Will Be Offering GammaCore Sapphire CV To All Customers For $1,250 Until Further Notice   Benzinga
Jul 28, 2020
09:00AM EDT  electroCore Highlights Publication Of Paper 'Non-invasive vagus nerve stimulation for primary headache: a clinical update' In 'Cephalalgia'   Benzinga
08:59AM EDT  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, Non-invasive vagus nerve stimulation for primary headache: a clinical update,1 in Cephalalgia, the official journal of the International Headache Society (IHS).   GlobeNewswire Inc
Jul 23, 2020
10:00AM EDT  ElectroCore Granted U.S. Patent Titled 'SYSTEMS AND METHODS FOR TREATING PATIENTS WITH DISEASES ASSOCIATED WITH REPLICATING PATHOGENS'   Benzinga
Jul 20, 2020
04:38PM EDT  EcoR1 Capital Reports 6.7% Passive Stake In GlycoMimetics   Benzinga
Jul 16, 2020
09:21AM EDT  In a release issued under the same headline on July 14, 2020, the companys cash was incorrectly stated as being as of the end of the first quarter. Note that the company ended the second quarter of 2020 with cash, cash equivalents and marketable securities of $18.9 million.   GlobeNewswire Inc
Jul 14, 2020
04:14PM EDT  ElectroCore Expects Q2 Total Revenue To Be $730K-$750K   RTTNews
04:05PM EDT  electroCore Sees Q2 Sales $730M-$750M   Benzinga
04:05PM EDT  electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select unaudited financial guidance for the second quarter and full year 2020.   GlobeNewswire Inc
05:11AM EDT  80 Biggest Movers From Yesterday   Benzinga
Jul 13, 2020
02:31PM EDT  Mid-Afternoon Market Update: Dow Jumps 400 Points; Equillium Shares Spike Higher   Benzinga
12:01PM EDT  Mid-Day Market Update: Benefytt Technologies Surges Following Acquisition News; NextCure Shares Slide   Benzinga
10:33AM EDT  Shares of electroCore, Inc. (ECOR) surged nearly three-fold on Monday morning after the company said the US FDA has issued an Emergency Use Authorization for the use of gammaCore Sapphire CV for the treatment of asthma exacerbations in COVID-19 patients.   RTTNews
07:08AM EDT  ElectroCore Reports FDA Emergency Use Authorization For Use Of GammaCore Sapphire CV   RTTNews
07:08AM EDT  electroCore Announces FDA Emergency Use Authorization For Use Of gammaCore Sapphire CV For Acute Treatment Of Asthma Exacerbations In Known Or Suspected COVID-19 Patients   Benzinga
07:00AM EDT  electroCore Announces FDA Emergency Use Authorization for use of   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC